Blog

Core One Labs Inc. (CSE:COOL), (OTCQB:CLABF), (Frankfurt:LD6, WKN:A3CSSU) is pleased to announce it has entered into a Letter of Intent with Medelys Laboratories International Inc. dated effective September 21, 2022, for the purpose of manufacturing the Company’s proprietary psychedelic active pharmaceutical ingredient (API) products for Core One and its subsidiaries. Under the Manufacturing Arrangement, it is intended that Medelys will develop and manufacture GMP-compliant patent-pending API-grade psychedelic compounds at a commercial scale for Core One by utilizing the Company’s proprietary intellectual property for the production of biosynthetic and synthetic psilocybin developed by Vocan Biotechnologies Inc. and Awakened Biosciences Inc., which are…

Mydecine Innovations Group Inc. (NEO: MYCO | OTC: MYCOF | FSE: 0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that, in connection with its previously announced Common Share Subscription Agreement with a third-party investor dated August 26, 2022 and the subsequent filing of a shelf prospectus supplement in connection therewith on September 7, 2022, the Company has closed the second tranche of the first issuance under the Subscription Agreement. The Company is also pleased to announce the appointment of John Ross as its Chief…

In this edition of Weekly Extractions, host Adam Tubero provides an update on a story we’ve been following closely over the past several weeks. For starters, MindMed’s stock has been quite volatile of late. It all started last week with the Weekly Extractions edition from August 13th where Adam calls out a letter written to the MindMed team from Scott Freeman. Next, Adam interviewed Scott Freeman. The video interview spanned two parts. Check out part 1 and part 2. MindMed popped up once again on August 24th in a unique story that tied their stock to Bed Bath and Beyond….

Delix Therapeutics, a neuroscience company developing novel disease-modifying therapeutics for psychiatric and neurological conditions, today announced the appointment of Dr. Eliseo Salinas as Head of Research & Development. Dr. Salinas will support the continued acceleration and expansion of Delix’s world-class discovery, preclinical, and clinical pipeline of non-hallucinogenic, neuroplasticity-promoting psychoplastogens. “With a library containing thousands of psychedelic-inspired, non-hallucinogenic compounds capable of rapidly inducing structural and functional reorganization of neural circuits to produce positive behavioral effects, Delix is working to deliver medicines that hold wide therapeutic potential. I look forward to adding Dr. Salinas and his deep experience in CNS to our scientific team,…

Clearmind Medicine Inc. (CSE: CMND | OTC Pink: CMNDF | FSE: CWY0), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, today announced it has filed a provisional patent application related to metabolic syndromes including obesity. The patent application is another result of the company’s ongoing collaboration with SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, and with the Hebrew University of Jerusalem. The patent application is the third application resulting from the collaboration with SciSparc, referring to the proprietary combination…